8307 (8307) Fair Value & Analysis

Healthcare · Market cap HK$44.8M

8 8307 8307 · HK

PriceHK$0.1130

Fair ValueHK$0.0500

Upside-55.8%

Quality49/100

Watch 8307 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.0400 – HK$0.0600

Fair value as of: Jul 3, 2026

From 22 valuation models · updated today

Share price −5.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1020 – HK$0.2220 · fair‑value band HK$0.0400 – HK$0.0600 · the HK$0.1130 price screens above the HK$0.0500 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8307 (8307) currently trades at HK$0.1130, while our model-based Fair Value estimate is HK$0.0500 — implying the stock looks roughly 55.8% overvalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 8307 generated revenue of HK$48.2M at a net margin of 1.9%. Revenue grew 8.0% year over year. It earns a return on equity of 19.9%. Net debt stands at HK$6.0M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$48.2M

Revenue growth (YoY) +8.0%

Net margin 1.9%

Return on equity 19.9%

Free cash flow HK$4.5M FY2026

Operating margin 3.2%

More key figures

EPS growth (YoY) -77.5%

Net debt HK$6.0M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

8307 reported revenue of HK$47.9M in FY2026 versus HK$49.1M in FY2022, a compound −0.7%/yr. Reported net income was HK$936K in FY2026, compounding −30.1%/yr from FY2022.

Revenue −0.7%/yr

FY22 HK$49.1M

FY23 HK$45.5M

FY24 HK$49.9M

FY25 HK$45.1M

FY26 HK$47.9M

Net income −30.1%/yr

FY22 HK$3.9M

FY23 −HK$3.5M

FY24 −HK$3.0M

FY25 −HK$3.4M

FY26 HK$936K

Is 8307 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$95.75	R$123.65	+29%
Fresenius SE FSNUY	$11.47	$8.55	-25%
5225 5225	8.71 MYR	4.87 MYR	-44%
IHHHF IHHHF	$1.71	$1.17	-32%
Tenet Healthcare Corporation THC	$164.77	$280.85	+70%
Rede D'Or São Luiz S.A RDOR3	R$32.50	R$46.04	+42%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 8307 (8307) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$0.0500 versus a price of HK$0.1130 — about −56% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 8307?

Our model-based fair value for 8307 is HK$0.0500 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$0.1130.

What is the quality score of 8307?

8307 has a Quality Score of 49/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 8307 (8307)?

8307 reported trailing-twelve-month revenue of about HK$48.2M (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 8307?

The net profit margin of 8307 is about 1.9%, meaning it keeps roughly 1.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.